Olfactomics Resect received Breakthrough device designation from the FDA

This is an important recognition for the importance of surgical margin assessment in breast cancer surgery.

Breakthrough status grants device priority in FDA communication and according to a recent initiative by Centers for Medicare & Medicaid Services a streamlined path to reimbursement!